| |
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now.
|
|
Today’s Big NewsJul 24, 2024 |
| By Nick Paul Taylor Sage Therapeutics and Biogen have extended the pharma industry’s multi-decade essential tremor losing streak. Three years after tolerability overshadowed efficacy, the partners have given up on SAGE-324 in the indication after failing to reduce tremors in a phase 2 trial designed to address their earlier problems. |
|
|
|
By Kevin Dunleavy An FDA advisory committee will discuss AstraZeneca’s application for Imfinzi in early-stage non-small cell lung cancer. The agency is asking external experts to weigh in on whether a new trial is needed to determine the contributions of the therapy on either end of surgery. |
By Conor Hale It’s a decision that comes after 28 years in government, and, according to Shuren, one that's overdue following the COVID-19 pandemic. |
By Andrea Park Castle Biosciences is keeping it “Real.” The diagnostics developer has partnered with Teddi Mellencamp Arroyave, a former cast member on “The Real Housewives of Beverly Hills” and the daughter of musician John Mellencamp, for a new campaign focused on raising awareness of melanoma. |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
By James Waldron Three months after scoring FDA approval for its hemophilia B gene therapy, Pfizer has posted phase 3 data suggesting it may be able to pull off the same success with a different candidate in hemophilia A. |
By Angus Liu A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics. |
By Kevin Dunleavy Korean CDMO juggernaut Samsung Biologics continued its sales surge in the second quarter, with its biosimilars unit, Samsung Bioepis, doing much of the heavy lifting. For the period, Samsung Bioepis achieved (PDF) sales of 530 South Korean won ($384 million), which was a 107% year-over-year increase and a 75% sequential boost. |
By Conor Hale Boston Scientific boosted its financial outlook for the remainder of 2024, after seeing a nearly 20% surge in the year-over-year sales of its cardiovascular devices. |
By Andrea Park Less than a year after announcing its first-ever acquisition, JPA Health has now completed a hat trick of buyouts. |
By Annalee Armstrong After reaching out to more than 200 companies to partner a Tourette syndrome therapy that showed the ability to beat standard of care last year, Asarina Pharma has come up empty and will fold. |
By Zoey Becker The company agreed to provide its insulin to patients in Minnesota for $35 per month, following a similar settlement the state reached with Eli Lilly. |
By Nick Paul Taylor Keen to reach the eyes and ears of healthcare professionals? Social media and podcasts could provide a way in, according to a CMI Media Group and Compas report about the media landscape. |
By Nick Paul Taylor Geron’s chief commercial officer is hitting the exit just as the party is getting started. Less than 50 days after the biotech won FDA approval for its first drug, the exec who played a starring role in creating its commercial strategy has announced he is leaving “to pursue other interests.” |
By Darren Incorvaia When it comes to developing new pain drugs, the placebo effect is a powerful but baffling force. Researchers have successfully mapped the neural circuits responsible for placebo pain relief in mice. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “Podnosis,” Micky Tripathi, Ph.D., National Coordinator for Health Information Technology at HHS, chats with Executive Editor Heather Landi about ONC’s achievements over the past 20 years, the agency’s current top priorities, the rapid adoption of AI in healthcare and more. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
